News
Analytical chemistry researchers at the University of Amsterdam's Van 't Hoff Institute for Molecular Sciences (HIMS) have ...
Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...
Senate To Begin Marathon Vote Series On Trump's "Big, Beautiful Bill" As GOP Eyes July 4 Deadline The Senate is set to kick off what's expected to be a marathon session Monday, after the chamber ...
“The benefits people report most often are way more energy, better workouts and faster recovery, higher libido, clearer ...
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...
Up 4:32 pm The Vanguard S&P 500 ETF closed Thursday at 564.20, up 0.8%. Game On for Meta 1:33 pm Bloomberg is reporting that ...
On Monday, Novo Nordisk, the producer of the popular weight loss drug, Wegovy, announced that it was ending its partnership with virtual healthcare provider Hims & Hers, and the market didn't like ...
The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been filed against Hims & Hers Health, Inc. ("Hims & Hers") ( NYSE: HIMS) on behalf ...
Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.
The heavy selling pressure might have exhausted for Hims & Hers Health (HIMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...
Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results